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Abstract We have previously demonstrated that LCAT is 
downregulated by TGF-P and that the regulation is post-
transcriptional and involves an increased rate of RNA degrada-
tion. Sodium butyrate affects the expression of several liver-
specific genes including some whose levels are altered during an 
acute-phase response. We have investigated the effect of sodium 
butyrate on LCAT activity and mRNA levels in HepG2 cells. 
Both the LCAT mRNA level and activity were reduced in a dose-
and time-dependent manner. The reduction of LCAT mRNA 
levels was not, however, due to an increased degradation of 
processed mRNA. The transcriptional activity of the LCAT gene 
as seen in run-on experiments was not affected by sodium 
butyrate, whereas the total level of LCAT transcripts was 
reduced. Thus, LCAT activity and mRNA level in HepG2 cells 
are decreased by sodium butyrate treatment by a post-transcrip-
tional mechanism, most likely involving increased degradation of 
pre-mRNA. 
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1. Introduction 
Sodium butyrate is a short-chain fatty acid produced by 
bacterial fermentation in the mammalian colon [1] where it 
inhibits cell proliferation and stimulates cell differentiation [2]. 
It affects many physiological processes in cultured mammalian 
cells, among these are the transcriptional activation of previ-
ously inactive genes and also the inactivation of a few active 
genes [3], reversible differentiation of cells [4] and blocking of 
cells in the G] phase of the cell cycle [5]. It has been reported 
that sodium butyrate can induce hypomethylation of genomic 
D N A in some cell systems [6] but also cause hypermethylation 
in others [7]. Additionally, sodium butyrate has been shown to 
suppress deacetylation of histones [8]. 
The differentiation-promoting effects of sodium butyrate 
have been demonstrated in several cell lines including rat 
and human hepatoma cells [9]. Sodium butyrate affects the 
expression of several liver-specific genes, among them proteins 
whose levels also are altered during an acute-phase response 
[10]. Treatment with sodium butyrate gives rise to changes in 
the chromatin structure and also to altered nuclear protein 
phosphorylation and methylation of proteins as well as 
D N A [11]. The exact mechanism by which sodium butyrate 
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causes alteration in gene expression in each case, however, is 
not known. 
The human lecithin:cholesterol acyltransferase (LCAT) is 
supposed to play a crucial role in the reverse transport of 
cholesterol from peripheral tissues [12] by catalyzing the ester-
ification of cholesterol in high density lipoprotein (HDL) par-
ticles, thus creating a concentration gradient for the flux of 
cholesterol from cell membranes into H D L . Recently, we and 
others have shown that L C A T belongs to a group of proteins 
that affect lipid and lipoprotein metabolism during the acute-
phase response [13,14]. Apolipoprotein A-I (apo A-I) and 
cholesterol ester transferring protein (CETP) also participate 
in the reverse cholesterol t ransport [15,16] and the level of apo 
A-I is reduced during the acute phase response [17]. The hu-
man hepatoma derived cell-line HepG2 has been found to 
express various liver-specific proteins, including LCAT, apo 
A-I and CETP, and is therefore in many respects a useful 
model of the human hepatocyte [18-20]. Sodium butyrate in-
creased the m R N A levels of both apo A-I and CETP in 
HepG2 cells [21,22]. Apo A-I is a strong activator of the 
esterifying reaction catalyzed by LCAT and contains a bind-
ing domain for the L C A T protein [23]. The regulation of 
L C A T transcription is not well understood. We have previ-
ously shown that its expression is downregulated by TGF-(3 
through decreased m R N A stability [13]. By perturbing L C A T 
expression in HepG2 cells using sodium butyrate, further in-
sight into these regulatory processes has been obtained. 
2. Materials and methods 
2.1. Materials 
Fetal calf serum (FCS) was from Biological Industries (Kibbutz 
Beth Haemek, Israel) and Dulbecco's modified Eagle's medium 
(DMEM), L-glutamine and trypsin-EDTA from Whittaker (Walker-
ville, MD, USA). Sodium butyrate, calf thymus DNA, human serum 
albumin (HSA, essentially fatty acid free), actinomycin D, lecithin and 
cholesterol were from Sigma (St. Louis, MO, USA). Apo A-I was 
isolated from human plasma [24]. Dynabeads were from Dynal 
(Oslo, Norway). [4-14C]Cholesterol was from Amersham, UK. Mag-
naCharge membranes (MSI, Westboro, MA, USA) were used for 
hybridization. 
2.2. Cell culture and treatment 
The human hepatoma-derived cell line HepG2 (ATCC HB8065) 
was grown in DMEM with 10% fetal calf serum and maintained in 
humidified 5% C0 2 , 95% air at 37°C. For experiments the cells were 
plated in 10 cm dishes at a density of 2X 106 and allowed to grow for 
4 days to reach about 75% confluence. The cells were then given fresh 
medium containing various concentrations of sodium butyrate (0.5-
5 mM). The medium was removed after 24 h and the cells were 
washed with PBS followed by incubation for another 24 h in se-
rum-free DMEM supplemented with the same concentrations of so-
dium butyrate. When indicated the cells were incubated with actino-
mycin D (5 ug/ml) in serum-free medium for 30 min prior to the 
addition of sodium butyrate. 
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Fig. 1. Dose-response curve for the effect of sodium butyrate on LCAT activity (A) and mRNA level (B) of HepG2 cells. Cells were treated 
with various concentrations of sodium butyrate (0-2 mM) for 24 h in the presence of DMEM with 10% FCS and further incubated at the 
same concentration of sodium butyrate in medium without serum for another 24 h. LCAT activity and mRNA levels were measured as de-
scribed in Section 2. Data are presented as mean±S.E.M. (« = 3, each in duplicate), *.P<0.05 and **P< 0.005 vs. control. 
2.3. LCAT activity 
LCAT activity was measured in medium from HepG2 cells by the 
addition of radiolabelled proteoliposomes (apo A-I:lecithin:cholester-
ol, 0.8:250:12.5 molar ratio) to medium using a modification of the 
method by Chen and Albers [25]. The final reaction volume was 1 ml. 
The substrate was preincubated for 20 min at 37°C with HSA (final 
concentration 0.5%). Medium and 2-mercaptoethanol (final concen-
tration 5 mM) were added, the mixture was incubated for 24 h at 
37°C and the enzyme activity was assayed by measuring the conver-
sion of cholesterol to cholesterol ester after separation by thin-layer 
chromatography. Preliminary experiments showed that the conditions 
used allowed zero order kinetics. Less than 15% of the substrate was 
converted. 
2.4. RNA analysis 
LCAT mRNA was isolated directly from PBS-washed cultured cells 
using oligo(dT) Dynabeads according to a procedure modified from 
that of Jakobsen et al. [26]. The cells were lysed and homogenized in 
buffer (0.1 M Tris-HCl, pH 8.0, 0.5 M LiCl, 10 mM EDTA, 1% LiDS, 
5 mM DTT) by shearing three times through a 21 gauge syringe. The 
RNA was blotted onto MagnaCharge membranes, hybridized 
(0.7XSSC, 1XSPEP, lxDenhardt) and washed (0.7XSSC, 1% 
SDS) at 68°C. LCAT and apo A-I mRNA levels were determined 
using human LCAT and apo A-I cDNA probes [27,28], To adjust 
for the amount of mRNA on the filters a cDNA probe for human 
GAPDH [29] was used. Random priming was used to label the DNA 
probes with [a-32P]dATP and [a-32P]dCTP. Linearly exposed auto-
radiograms were scanned in a Shimadzu CS-9000 densitometer. 
2.5. Nuclear run-on transcription assay 
Nuclei were prepared as described by Graves et al. [30] with some 
modifications. Untreated and treated (24 h) HepG2 cells from 10 cm 
dishes were scraped into ice-cold PBS, centrifuged and resuspended in 
50 ul PBS. Cells were lysed by the addition of 450 ul Nonidet P-40 
buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5% 
Nonidet P-40). After 5 min incubation on ice and centrifugation at 
265 Xg and 4°C, the sedimented nuclei were resuspended in storage 
buffer (50 mM Tris-HCl pH 8.0, 40% glycerol, 5 mM MgCl2, 0.1 mM 
EDTA, 70 mM KC1, 2.5 mM DTT). 
Transcription assays were performed as described by Bartalena et 
al. [31] and Baumhueter et al. [32]. Nuclei (1-3 X 106) were incubated 
in the storage buffer in the presence of 0.62 mM rATP, 0.31 mM 
rGTP, 0.31 mM rCTP, 80 U RNasin and 250 uCi [a-32P]UTP (800 
Ci/mmol) at 27°C in a total volume of 400 ul. After 20 min 3 ul 10 
mM UTP was added and the reaction mix was further incubated at 
37°C for 15 min. The reaction was stopped by adding DNase I (1 mg/ 
ml) and 200 |ig tRNA. The labelled RNA was purified using protein-
ase K, phenol/chloroform extractions and ethanol/ammonium acetate 
precipitation. The labelled RNA species were then hybridized for 
3 days onto nylon membranes with immobilized cDNAs for apo A-
I, LCAT, GAPDH and pBR322 DNA as control. Hybridizations 
were performed at 42°C for 72 h in 30% formamide, 300 mM 
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Fig. 2. Time course of the effect of sodium butyrate on LCAT activity (A) and mRNA level (B) of HepG2 cells. Cells were treated with 2 mM 
sodium butyrate in serum-free medium after a 24 h preincubation in medium with 10% FCS and the same concentration of sodium butyrate. 
At the indicated times, samples of cells and medium were analyzed for LCAT activity and mRNA levels as described in Section 2. Data are 
presented as mean ± S.E.M. (» = 4, each in duplicate), *P<0.05 and "P< 0.005 vs. control. 
NaCl, 10 mM EDTA, 100 mM Tris-HCl pH 7.2, 0.2% SDS, 0.4% 
Ficoll and 100 ug/ml tRNA. Filters were washed 2X15 min at 42°C in 
10 mM Tris-HCl pH 7.5, 300 mM NaCl, 2 mM EDTA and 0.1% SDS 
and 2x 15 min at 65°C in 10 mM Tris-HCl pH 7.5, 60 mM NaCl, 0.1 
mM EDTA, 0.1% SDS followed by autoradiography at -70°C. Cold 
nuclear run-on transcription assays were performed similarly using 
only unlabelled nucleotides. The purified nuclear RNA was then sep-
arated on a denaturing agarose gel, blotted onto MagnaCharge mem-
branes and hybridized using labelled LCAT and GAPDH cDNA as 
probes. 
3. Results 
3.1. Dose dependence and time course of the effect of sodium 
butyrate on LCAT activity and LCAT mRNA 
To investigate the influence of sodium butyrate on expres-
sion of the LCAT gene, HepG2 cells were treated with various 
concentrations of sodium butyrate for different time intervals. 
Kaptein et al. [21] have shown that sodium butyrate induces 
an increase in the level of mRNA for apo A-I as well as in the 
secretion of this protein after a lag period of approximately 24 
h. Based on their results we incubated HepG2 cells with 0.5-2 
mM sodium butyrate for 24 h in medium containing serum 
followed by a further incubation in serum-free medium at the 
same butyrate concentrations for another 24 h. (Incubation in 
serum-free medium beyond 24 h in itself affected LCAT lev-
els.) Control cells were incubated for 24 h in medium contain-
ing serum followed by incubation in serum-free medium for 
the same interval. 
Sodium butyrate (2 mM) caused a 5-fold decrease in the 
LCAT activity after 48 h (Fig. 1A). This was accompanied by 
a decrease in the level of LCAT mRNA to about 35% of the 
control value (Fig. IB). A significant decrease in LCAT activ-
ity was seen at concentrations of 0.5 mM sodium butyrate or 
higher (P<0.05); for LCAT mRNA a significant decrease 
was only observed at or about 1.5 mM (P<0.05). 
The time dependence of the sodium butyrate effect was 
investigated by treating HepG2 cells with 2 mM sodium bu-
tyrate for 1, 6, 11 and 24 h in serum-free medium. After 6 h 
LCAT activity in the medium from sodium butyrate-treated 
cells had declined to 27% of control values. In contrast to the 
increase of apo A-I mRNA observed by Kaptein et al. [21], we 
detected a decline in LCAT mRNA to about half of the con-
trol value after 24 h (Fig. 2B). This level remained unchanged 
during the next 24 h. LCAT activity in the medium from the 
butyrate-treated cells had decreased to about 16% of that in 
medium from the control cells (Fig. 2A). 
3.2. Effect of sodium butyrate on mRNA half-life 
The effect of sodium butyrate was then studied in experi-
ments where RNA synthesis was inhibited by actinomycin D 
as described. HepG2 cells were grown in the absence and 
presence of sodium butyrate. Actinomycin D was added 30 
min before sodium butyrate. From these cultures mRNA was 
isolated over a time course of 48 h. LCAT mRNA from un-
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Fig. 3. Effect of sodium butyrate on LCAT and apo A-I mRNA half-life in HepG2 cells. The cells were treated with actinomycin D (5 ng/ml) 
in the absence or presence of sodium butyrate (2 mM). mRNA was isolated at the indicated times (0, 1, 3 and 24 h) and analyzed as described 
in Section 2. Data are given in percent of the value for mRNA at the start of the experiment. 
treated and sodium butyrate-treated cells appeared to decay 
equally slowly (Fig. 3), with a half-life of approximately 8 h. 
Also apo A-I mRNA decayed at essentially the same rate in 
butyrate-treated and control cells (Fig. 3). 
3.3. Effect of sodium butyrate on the transcriptional activity of 
the LCAT gene 
To determine whether the decrease in LCAT mRNA levels 
in HepG2 cells after treatment with sodium butyrate was 
caused by decreased transcription of the LCAT gene, run-on 
experiments were performed on nuclei from untreated HepG2 
cells and from cells treated for 24 h with sodium butyrate. In 
these assays, only transcripts which are already initiated are 
elongated, thus giving an accurate measure of the level of 
transcription at the time of the nuclear isolation. In such 
run-on experiments there was no change in the transcription 
rate of the LCAT gene after treatment with sodium butyrate 
(Fig. 4) even though sodium butyrate significantly reduced the 
level of LCAT mRNA seen by Northern blot analysis (Figs. 
IB and 2B). We therefore decided to visualize the LCAT pre-
mRNA levels by cold run-on assays, isolating nuclear RNA 
and running it out on a denaturing gel, blotting and hybrid-
Relative transcription rate in the presence of butyrate (2 mM) 
Fig. 4. Effect of sodium butyrate on the transcriptional activity of the LCAT and apo A-I genes. Relative transcription rates were determined 
in nuclei from HepG2 cells untreated or treated with 2 mM sodium butyrate for 24 h. Nuclei were isolated and run-on assays performed as de-
scribed in Section 2. Data are given in percent of the transcription rate of control nuclei and represent the means of two independent run-on 
assays. 
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Cold run-on experiment 
Fig. 5. Effect of sodium butyrate on total LCAT RNA transcripts in HepG2 cells as observed in cold run-on assays. Nuclei from cells un-
treated or treated with sodium butyrate (2 mM) were treated as described for run-on assays in Section 2. Total RNA was isolated and analyzed 
by Northern blots using LCAT and GAPDH cDNAs as probes. Arrows indicate the position of mature LCAT and GAPDH mRNA. 
izing with labelled LCAT and GAPDH probes. As expected, a 
'haze' was seen of RNA molecules of 1.5^4.2 kb, representing 
LCAT pre-mRNA at various stages of processing. Control 
hybridizations with GAPDH gave expected sizes (1.3-5.3 
kb). A marked difference was seen between nuclear RNA 
samples from butyrate-treated and control cells, showing 
that LCAT transcripts, although initiated with equal fre-
quency in treated and control cells (Fig. 4), was degraded 
more rapidly under butyrate treatment (Fig. 5). 
Apo A-I mRNA is enhanced in HepG2 cells after treatment 
with sodium butyrate [21]. This increase is apparently partly 
due to an increased transcription of the apo A-I gene, since 
the transcriptional rate of the apo A-I gene after treatment 
with 2 mM sodium butyrate for 24 h increased approximately 
50% (Fig. 4). 
4. Discussion 
The human hepatoma-derived cell line HepG2 retains many 
characteristics of the normal differentiated hepatocyte. It syn-
thesizes and secretes apolipoproteins [19]. Also LCAT is se-
creted and LCAT mRNA is observed in Northern blot anal-
ysis [18,33]. The HepG2 line therefore constitutes a suitable 
model system to study expression of the LCAT gene. Treat-
ment of HepG2 cells with sodium butyrate led to a decrease in 
LCAT expression. We have examined this effect of sodium 
butyrate on LCAT expression and its underlying causes. 
The decrease in LCAT mRNA levels was dose- and time-
dependent with respect to butyrate treatment and accompa-
nied by lowered LCAT activity in the culture medium. So-
dium butyrate did not alter the rate of degradation of proc-
essed LCAT mRNA. LCAT expression was decreased by a 
post-transcriptional mechanism since the transcription rate as 
measured in run-on experiments was unaltered when butyrate-
treated and control cells were compared. We conclude that the 
reduced steady-state LCAT mRNA level must be due to 
events taking place in the interval between transcription and 
degradation of processed mRNA. Evidence rendering further 
support for this hypothesis comes from the cold run-on ex-
periments. When total nuclear RNA was subjected to agarose 
electrophoresis, blotted and hybridized to a LCAT probe, a 
smear of RNA molecules of apparent sizes approximately 1.5-
4.2 kb is observed, as expected for LCAT pre-mRNA consist-
ing of molecules at all stages of processing. In nuclear RNA 
from butyrate-treated cells there is a significant and clearly 
visible reduction in the amount of such RNA available for 
hybridization to the LCAT probe (Fig. 5). These data indicate 
that the action of butyrate in regulating LCAT mRNA levels 
has to do with regulation of pre-mRNA processing and stabil-
ity and that butyrate induces a more rapid breakdown of pre-
mRNA which is not fully processed. 
We have previously reported that LCAT mRNA and activ-
ity were downregulated by a post-transcriptional mechanism 
when HepG2 cells were treated with TGF-P [13]. The present 
data suggest that TGF-P and sodium butyrate act via similar 
mechanisms in downregulating LCAT activity. It has been 
reported that sodium butyrate can induce alterations in 
DNA methylation [6,7]. Control experiments (Skretting, un-
published) showed no differences in the pattern of cleavage of 
LCAT genomic DNA (including the promoter region) by a 
number of methylation-sensitive restriction enzymes. 
Apo A-I is the most efficient activator of the LCAT reac-
tion in vitro. In vivo, apo A-I is a part of the discoidal, 
nascent HDL particle which takes up unesterified cholesterol 
from cell membranes. This cholesterol is esterified by LCAT 
and the HDL particle is transformed into a spherical, mature 
particle with a cholesterol ester core. Apo A-I interacts with 
the LCAT protein to activate the enzyme through a specific 
domain in the apo A-I protein. Patients with various forms of 
apo A-I deficiency have lowered LCAT activity in plasma and 
patients with familial LCAT deficiency or fish-eye disease 
have lowered amounts of apo A-I in plasma [34-36]. These 
findings may suggest that there are common elements in the 
regulation of the expression of the LCAT and apo A-I genes. 
For apo A-I mRNA the regulation by TGF-P seemed to be 
both transcriptional and post-transcriptional. Sodium buty-
rate has been reported to stimulate the synthesis of apo A-I 
in HepG2 cells [21]. Our results show that this is partly caused 
by an increased rate of apo A-I gene transcription (and pos-
sibly also by an increased rate of pre-mRNA processing) in 
the presence of an essentially unaltered apo A-I mRNA stabil-
ity. 
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In summary, the present study demonstrates that sodium 
butyrate downregulates the expression of the L C A T gene in 
HepG2 cells by a post-transcriptional mechanism, most likely 
by increased degradation of pre-mRNA, whereas apo A-I ex-
pression is upregulated, at least in part through an increased 
transcription rate. 
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